Paradigm Biopharmaceuticals (ASX:PAR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Paradigm Biopharmaceuticals (ASX:PAR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
PPS Shows Significant Pain Benefit in Rest of World Analysis
Paradigm reports positive ROW Phase 3 iPPS results, but trial remains halted amid administration
Expiry of PAROB Listed Options
Notification of cessation of securities - PAR
Update on Data Review and Convertible note redemption
Continuation of Suspension from Quotation
ASX continues Paradigm Biopharmaceuticals suspension after voluntary administrator appointment
Appointment of Voluntary Administrators
Paradigm Biopharmaceuticals enters voluntary administration as administrators assess viability and restructuring options
Board Initiates Voluntary Administration
Paradigm enters voluntary administration after failed Phase 3 interim result
Continuation of Voluntary Suspension
Paradigm seeks continued trading suspension pending Phase 3 data review and financial assessment
Notification of cessation of securities - PAR
Agreement to Return US$2M to Obsidian
Paradigm to return US$2M and cancel convertible notes as Phase 3 trial review continues
Phase 3 Interim Result Below Continuation Threshold
Paradigm Phase 3 osteoarthritis trial falls below continuation threshold; trading suspension requested
Suspension from Quotation
Paradigm Biopharmaceuticals suspended pending PARA_OA_012 Phase 3 interim results
Trading Halt
Application for quotation of securities - PAR
Dr Daniel Furtner appointed Chief Medical Officer
Application for quotation of securities - PAR
Notice under Section 708A
Notification regarding unquoted securities - PAR
Drawdown of Tranche 4 under the Convertible Note Facility
Paradigm draws remaining US$2m Tranche 4 to fund Phase 3 osteoarthritis trial
Application for quotation of securities - PAR
Melbourne Investor Lunch
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Paradigm completes Phase 3 recruitment, raises A$21.74m, reports $56.3m loss, eyes key clinical milestones
Application for quotation of securities - PAR
80% Safety Review Complete, September IA on Track
Application for quotation of securities - PAR
June 2026 Quarterly Activities Report & Appendix 4C
Paradigm completes Phase 3 enrolment, raises A$21.38 million, targets Interim Analysis in September 2026
Notification of cessation of securities - PAR
Paradigm Receives $5.75m R&D Tax Incentive Refund
Paradigm secures $5.75 million in Australian Government R&D tax refunds to support Phase 3 osteoarthritis program
Application for quotation of securities - PAR